Onkologie. 2020:14(5):213-218 | DOI: 10.36290/xon.2020.076

Radiotherapy and immunotherapy are irreplaceable in the treatment of cancer

Denisa Pohanková, Jindřich Kopecký
Klinika onkologie a radioterapie LF a FN Hradec Králové

The fact that ionizing radiation can be not only an immunosuppressive has been known for a long time. However, until the advent of immunotherapy with checkpoint inhibitors, there has been increased interest in the possibility of using immunotherapy and radiotherapy in combination. Although this combination is accepted already as beneficial, there are still many issues that are yet to be solved, such as the timing of both modalities, the definition of optimal doses and regimen. This review tries to summarize the essential information we have about this combination, which can also serve as a clue in planning the treatment strategy.

Keywords: immunotherapy, radiotherapy, abscopal effect, anti-CTLA-4, anti-PD-1.

Published: November 19, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pohanková D, Kopecký J. Radiotherapy and immunotherapy are irreplaceable in the treatment of cancer. Onkologie. 2020;14(5):213-218. doi: 10.36290/xon.2020.076.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol 2015; 1(9): 1325-32. Go to original source... Go to PubMed...
    2. Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: a winning new combination? Ther Adv Med Oncol 2018; 10: 1758835918768240. Go to original source... Go to PubMed...
    3. Carvalho HA, Villar RC. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo) 2018; 73(Suppl. 1): e557s. Go to original source... Go to PubMed...
    4. Orth M, Lauber K, Niyazi M, et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys 2014; 53(1): 1-29. Go to original source... Go to PubMed...
    5. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 2014; 32(26): 2847-54. Go to original source... Go to PubMed...
    6. Eriksson D, Stigbrand T Radiation-induced cell death mechanisms. Tumour Biol 2010; 31(4): 363-372. Go to original source... Go to PubMed...
    7. Mole RH Whole body irradiation; radiobiology or medicine? Br J Radiol 1953; 26(305): 234-41. Go to original source... Go to PubMed...
    8. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 2017; 14(6): 365-379. Go to original source... Go to PubMed...
    9. Schaue D, Kachikwu EL, McBride WH. Cytokines in radiobiological responses: a review. Radiat Res 2012; 178(6): 505-23. Go to original source... Go to PubMed...
    10. Demaria S, ormenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012; 2: 95. Go to original source... Go to PubMed...
    11. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016; 40(1): 25-37. Go to original source... Go to PubMed...
    12. Golden EB, Frances D, Pellicciotta I, et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014; 3: e28518. Go to original source... Go to PubMed...
    13. Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol 2015; 25(1): 28-33. Go to original source... Go to PubMed...
    14. Vanpouille-Box C, Formenti SC, Demaria S. Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clin Cancer Res 2018; 24(2): 259-265. Go to original source... Go to PubMed...
    15. Teng F, Kong L, Meng X, et al. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. Cancer letters 2015; 365(1): 23-29. Go to original source... Go to PubMed...
    16. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013; 105(4): 256-65. Go to original source... Go to PubMed...
    17. Koller KM, Mackley HB, Liu J, et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther 2017; 18(1): 36-42. Go to original source... Go to PubMed...
    18. Schmidberger H, Rapp M, Ebersberger A, et al. Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. Strahlenther Onkol 2018; 194(12): 1144-1151. Go to original source... Go to PubMed...
    19. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 2015; 92(2): 368-75. Go to original source... Go to PubMed...
    20. Kim HJ, Chang JS, Roh MR, et al. Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. Frontiers in Oncology 2019; 9(835). Go to original source... Go to PubMed...
    21. Anahid S, Afra O. The Combination of Radiotherapy with Pembrolizumab in the Treatment of Metastatic Melanoma Patients: a Systematic Review. SN Comprehensive Clinical Medicine 2020. Go to original source...
    22. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18(7): 895-903. Go to original source... Go to PubMed...
    23. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377(20): 1919-1929. Go to original source... Go to PubMed...
    24. Campbell AM, Cai WL, Burkhardt D, et al. Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology, Biology, Physics 2019; 105(1): S36-S37. Go to original source...
    25. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24(7): 1813-1821. Go to original source... Go to PubMed...
    26. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer 2016; 4: 51. Go to original source... Go to PubMed...
    27. Marshall R, Popple A, Kordbacheh T, et al. Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity? Clin Oncol (R Coll Radiol) 2017; 29(4): 207-217. Go to original source... Go to PubMed...
    28. Cushman TR, Caetano MS, Welsh JW, Verma V. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. Immunotherapy 2018; 10(10): 851-0. Go to original source... Go to PubMed...
    29. Käsmann L, Eze C, Dantes M, et al. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours - a German radiation oncology survey. European Journal of Cancer 2019; 108: 50-54. Go to original source... Go to PubMed...
    30. Young KH, Baird JR, Savage T, et al. Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS One 2016; 11(6): e0157164. Go to original source... Go to PubMed...
    31. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74(19): 5458-68. Go to original source... Go to PubMed...
    32. An Y, Jiang W, Kim BYS, et al. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 2017; 125(1): 80-88. Go to original source... Go to PubMed...
    33. Patel KR, Shoukat S, Oliver DE, et al. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol 2017; 40(5): 444-450. Go to original source... Go to PubMed...
    34. Liniker E, Menzies AM, Kong BY, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology 2016; 5(9): e1214788. Go to original source... Go to PubMed...
    35. Samstein R, Rimner A, Barker CA, Yamada Y. Combined Immune Checkpoint Blockade and Radiation Therapy: Timing and Dose Fractionation Associated with Greatest Survival Duration Among Over 750 Treated Patients. International Journal of Radiation Oncology, Biology, Physics 2017; 99(2): S129-S130. Go to original source...
    36. Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2013; 2(6): 899-906. Go to original source... Go to PubMed...
    37. Hellevik T, Martinez-Zubiaurre I. Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol 2014; 4: 1. Go to original source... Go to PubMed...
    38. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203(5): 1259-71. Go to original source... Go to PubMed...
    39. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64(21): 7985-94. Go to original source... Go to PubMed...
    40. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012; 83(4): 1306-10. Go to original source... Go to PubMed...
    41. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174(12): 7516-23. Go to original source... Go to PubMed...
    42. Camphausen K, Moses MA, Ménard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 2003; 63(8): 1990-3.
    43. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15(17): 5379-88. Go to original source... Go to PubMed...
    44. Aryankalayil MJ, Makinde AY, Gameiro SR, et al. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res 2014; 182(2): 139-48. Go to original source... Go to PubMed...
    45. Schaue D, Comin-Anduix B, Ribas A, et al. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 2008; 14(15): 4883-90. Go to original source... Go to PubMed...
    46. Tabi Z, Spary LK, Coleman S, et al. Resistance of CD45RA - T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. J Immunol 2010; 185(2): 1330-9. Go to original source... Go to PubMed...
    47. Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 2017; 8: 15618. Go to original source... Go to PubMed...
    48. Qin R, Olson A, Singh B, et al. Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. Int J Radiat Oncol Biol Phys 2016; 96(1): 72-77. Go to original source... Go to PubMed...
    49. Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015; 4(11): e1046028. Go to original source... Go to PubMed...
    50. Patel KR, Oliver DE, Okwan-Dadu D, et al. Abstract 247: Comparing radiation therapy and ipilimumab to ipilimumab alone in metastatic melanoma patients. Cancer Research 2015; 75(15 Supplement): 247-247. Go to original source...
    51. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys 1996; 34(1): 251-66. Go to original source... Go to PubMed...
    52. Marciscano A, Nirschl TR, Francica BJ, et al. Does Prophylactic Nodal Irradiation Inhibit Potential Synergy Between Radiation Therapy and Immunotherapy. International Journal of Radiation Oncology Biology Physics 2016; 96. Go to original source...
    53. Marciscano AE, Ghasemzadeh A, Nirschl TR, et al. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy. Clin Cancer Res 2018; 24(20): 5058-5071. Go to original source... Go to PubMed...
    54. Hynková L, Doleželová H. Nežádoucí účinky radioterapie a podpůrná léčba u radioterapie nádorů hlavy a krku. Oncology 2008; 2(2): 88-90.
    55. Kyllarová A, Kubeček O, Trojanová P, et al. Toxicita imunoterapie. Oncology 2017; 11(2): 83-87. Go to original source...
    56. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520(7547): 373-377. Go to original source... Go to PubMed...
    57. Hiniker SM, Reddy SA, Maecker HT, et al. A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys 2016; 96(3): 578-88. Go to original source... Go to PubMed...
    58. Tang C, Welsh JW, de Groot P, et al. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res 2017; 23(6): 1388-1396. Go to original source... Go to PubMed...
    59. Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 2016; 27(3): 434-41. Go to original source... Go to PubMed...
    60. Bang A, Wilhite TJ, Pike LRG, et al. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 2017; 98(2): 344-351. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.